Key Takeaways Boston Scientific's EP sales jumped 63% in Q3, fueled by robust FARAPULSE-driven growth.FDA approval expands BSX's FARAPULSE use to treat persistent atrial fibrillation patients.Boston Scientific targets 50% PFA penetration by end-2025, rising to 80% globally by 2028.Boston Scientific’s (BSX) Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field Ablation (“PFA”) System, drove stro ...